Pristimerin is a naturally occurring triterpenoid that causes cytotoxicity in several cancer cell lines. However, the mechanism of action for the cytotoxic effect of pristimerin has not been unexplored. The purpose of this study was to investigate the effect of pristimerin on cytotoxicity using the epidermal growth factor receptor 2 (HER2)-positive SKBR3 human breast cancer cell line. Pristimerin inhibited proliferation in dose-and time-dependent manners in cells. We found it to be effective for suppressing HER2 protein and mRNA expression. Fatty acid synthase (FASN) expression and FASN activity were downregulated by pristimerin. Adding of exogenous palmitate, the end product of de novo fatty acid synthesis, reduced the proliferation activity of pristimerin. The changes in HER2 and FASN expression induced by pristimerin altered the levels of Akt and mitogen-activated protein kinase (MAPK) phosphorylation (Erk1/2, p38, and c-Jun N-terminal kinase (JNK)). Pristimerin lowered the levels of phosphorylated mammalian target of rapamycin (mTOR) and its downstream targets such as phosphoprotein 70 ribosomal protein S6 kinase and 4E binding protein1. Pristimerin inhibited migration and invasion of cells, and co-treatment with the mTOR inhibitor rapamycin additionally suppressed these activities. Pristimerin-induced apoptosis was evaluated using Western blotting for caspase-3, -8, -9, and poly (ADP-ribose) polymerase expression and flow cytometric analysis for propidium iodide labeling. These results suggest that pristimerin is a novel HER2-downregulated compound that is able to decrease fatty acid synthase and modulate the Akt, MAPK, and mTOR signaling pathways to influence metastasis and apoptosis. Pristimerin may be further evaluated as a chemotherapeutic agent for HER2-positive breast cancers.
Natural compounds have become more important in anti cancer drug development as they are more tolerable to the human body. 1) Pristimerin, a naturally occurring quinoneme thide triterpenoid compound, is a traditional medicine derived from the Celastraceae and Hippocrateacea families and has long been used as an anti-inflammatory, antioxidant, antima larial, and insecticidal agent. 2, 3) Some of the plants containing pristimerin, such as Maytenus chuchuhuasca and Maytenus laevis, have been used traditionally to treat arthritis and skin cancer in South America. 4) Pristimerin has promising clinical potential as both a therapeutic and chemopreventive agent for various cancers. 5) For example, pristimeirin induces apoptotic cell death in MDAMB231 breast cancer cells in a caspasedependent manner, as well as in human acute myeloid leukemia. 6, 7) Pristimerin has several mechanisms of inducing cell death, including potent proteasomal inhibition, 8) sup pression of nuclear factorκB (NFκB) activity and cyclin D1 expression, 9) and reactive oxygen species-dependent c-Jun Nterminal kinase (JNK) and poly (ADPribose) polymerase1 (PARP1) activation. 10) However, the molecular target of apo ptosis induction by pristimerin remains largely unknown.
One of the most common molecular alterations associated with the malignant phenotype of breast cancer is overexpres sion of epidermal growth factor receptor2 (also known as HER2).
11) The HER2 receptor (185 kDa) is the protein product of the HER2 protooncogene and a member of the epidermal growth factor receptor family of transmembrane tyrosine kinases. HER2 overexpression can transform normal mam mary epidermal cells and is amplified in 25-30% of breast cancers; it has also been associated with an aggressive form of the disease characterized by significantly shortened sur vival time. 12) Aberrant upregulation of HER2 is found in many cancer types and promotes cell survival, tumor growth, metastasis, and angiogenesis. 13, 14) HER2 dimerizes with mem bers of the epidermal growth factor receptor (EGFR) family (EGFR, HER3, and HER4) to induce downstream signaling cascades, including phosphoinositol 3kinase (PI3K)/Akt and Ras/mitogenactivated protein kinase (MAPK), which control cell growth, motility, cell invasiveness, and differentiation. 15, 16) The humanized monoclonal antibody trastuzumab (Herceptin), which binds the HER2 extracellular region, is approved for treatment of HER2positive breast cancer. 17) Nevertheless, only a fraction of patients with HER2positive disease respond to trastuzumab in metastatic settings, 18) implying that many advanced cancers are trastuzumabresistant. The antitumor mechanism of trastuzumab action remains unclear.
The mammalian target of rapamycin (mTOR) signaling is already active in HER2positive breast cancers. 19) mTOR is a serine/threonine kinase and a link between oncogenic PI3K/ Akt signaling and critical downstream pathways that drive cancer cell growth and survival. 20) mTOR kinase exists in two complexes called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTOR interacts with regulatory associ ated protein of mTOR (raptor), PRAS40, and mLST8 to form mTORC1, the sensitive target of rapamycin that phosphorylates downstream targets of phosphoprotein 70 ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E bind ing protein 1 (4EBP1). It also controls capdependent protein translation, or rapamycininsensitive companion of mTOR (rictor), mSIN1, PRR5/Protor, and mLST8 to form mTORC2, which is sensitive to acute rapamycin treatment and phosphor ylates Akt at Ser473. 21) mTOR phosphorylates downstream mediators leading to the regulation of cell cycle progression, cell growth, and angiogenesis. mTOR signaling increases in most common human cancers, and activation of mTORdepen dent protein translation correlates with malignant progression, adverse prognosis, and resistance to both chemotherapy and targeted therapy such as trastuzumab. 22) Clinical trials using rapamycin analogues, such as temsirolimus and everolimus, which are registered for treating advanced cancer, have vali dated the importance of mTOR inhibition as an anticancer treatment strategy. 23) These mechanisms indicate that mTOR inhibiting agent in HER2positive cancers could have a potent anticancer effect.
In this study, we investigated the effect of pristimerin on cytotoxicity using a HER2-positive SKBR3 human breast cancer cell line.
MATERIALS AND METHODS

Materials
McCoy's 5A and trypsin/ethylenediaminetetra acetic acid (EDTA) were purchased from Thermo Scientific HyClone (Logan, UT, U.S.A.). Fetal bovine serum (FBS) and penicillin/streptomycin were obtained from GIBCO/BRL Life Technologies (Grand Island, NY, U.S.A.). Antibodies to PHER2, HER2, fatty acid synthase (FASN), PErk1/2, Pp38, p38, PJNK, JNK, PmTOR, mTOR, Pp70S6K, p70S6K, P 4EBP1, 4EBP1, caspase3, caspase8, caspase9, PARP were purchased from Cell Signaling Technology, Inc. (Danvers, MA, U.S.A.), and Erk1/2, βactin from Santa Cruz (Santa Cruz, CA, U.S.A.). Horseradish peroxidase-conjugated antimouse and antirabbit antibodies were from Transduction Lab (Lexington, KY, U.S.A. Isolation of Pristimerin Dry roots (4 kg) of S. cochinchi nensis were powdered and extracted with methanol at room temperature for 48 h and the solvent was evaporated under reduced pressure to get a dry extract (methanol extract, 79 g). This extract was suspended in water and partitioned with n-hexane and the organic solvent was concentrated to yield a hexane fraction (24 g). A part of this fraction (10 g) was chromatographed over a silica gel column and eluted with n hexane-ethyl acetate (10 : 0, 9 : 1, 8 : 2→ 1 : 9, 0 : 10). Pristimerin (2 g) was crystallized out from the selected fraction (eluted with n-hexane-ethyl acetate, 8 : 2, 7 : 3) with eluted solvent and then in n-hexane-dichloromethane (2.5 : 7.5). The purity of pristimerin was determined as 95% by high-performance liq uid chromatography. The structure of pristimerin is illustrated in Fig. 1A .
Cell Culture Human breast carcinoma SKBR3 cells were purchased from American Type Culture Collection (ATCC) (Manassas, VA, U.S.A.). Cells were grown in McCoy's 5A media supplemented with 10% (v/v) FBS, penicillin (100 U/ mL)/streptomycin (100 µg/mL) at 37°C in a humidified CO 2 (5%)-controlled incubator.
Western Blotting Analysis Cells were incubated with pristimerin for 24 h, and washed twice in cold phosphate buff ered saline (PBS). Cells were lysed with lysis buffer (10 mm Tris, pH 7.4, 150 mm NaCl, 1 mm EDTA, 1% TritonX-100, 0.5% NP-40, 1 mm propidium iodide (PI), 1 mm dithiothrei tol (DTT), 1 mm phenylmethylsulfonyl fluoride (PMSF)) and placed on ice for 1 h with occasional vortexing. Centrifugation followed at 10000 rpm for 10 min and each cell lysates (50 µg) were subjected to sodium dodecyl sulfate (SDS)polyacryl amide gel electrophoresis (PAGE) and transferred to poly vinylidene difluoride (PVDF) membrane. Blots were blocked with 5% skim milk in PBS containing 0.05% Tween-20 for 1 h at 25°C, then incubated with primary antibodies, fol lowed by incubation with antirabbit or antimouse horserad ish peroxidase-conjugated IgG and visualized with enhanced chemiluminescence.
Cell Proliferation Assay Cells were seeded at 5×10 3 cells/ mL in 96well microplates and allowed to attach for 24 h. Pris timerin was added to the medium at various concentrations up to 50 µm and different duration. After treatment, cell cy totoxicity and/or proliferation was assessed by Cell Counting Kit-8 (CCK-8). Briefly, highly water-soluble tetrazolium salt, WST-8[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)2Htetrazolium, monosodium salt], produced an orange colored watersoluble product, formazan. The amount of formazan dye generated by dehydrogenases in cells was directly proportional to the number of living cells. CCK8 (10 µL) was added to each well and incubated for 3 h at 37°C, then cell proliferation and cytotoxicity were assessed by measuring the absorbance at 450 nm using microplate reader. Three replicated wells were used for each experimental condi tion.
RNA Isolation and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) After vehicle and drug treat ment, cells were subjected to total RNA isolation by using RNAeasy mini kit. RNA concentrations were determined by measuring absorption at 260 nm in a spectrophotometer. Aliquots of 1 µg of total RNA from each sample were reverse transcribed to cDNA using an AccuPower CycleScript RT PreMix (dT20) according to manufacturer's instructions from Bioneer Inc. (Daejeon, Korea). PCR primers used in this study included; HER2: 5′-AGC CGC GAG CAC CCA AGT and 5′-TTG GTG GGC AGG TAG GTG AGT T; β-actin: 5′-AAA CTG GAA CGG TGA AGG TG-3′ and 5′-CTC AAG TTG GGG GAC AAA AA-3′. HER2 and βactin cDNAs were am plified with 25 cycles to ensure that the PCR reactions were performed in the linear range using the following PCR profile: 98°C for 30 s, 57°C for 1 min, and 72°C for 1 min. The PCR products were separated on a 2% agarose gel and detected by ethidium bromide staining.
Fatty Acid Synthesis Activity The preparation, stor age and use of fatty acid synthase from chicken liver were performed as described previously. 24) Ammonium sulfate pre cipitations, gel filtration and anion exchange chromatography were used for purification. FASN has >95% purity as esti mated from SDSPAGE with Coomassie blue staining. FASN was incubated with reaction buffer (200 mm KP buffer, pH 7.0, 2.5 mm DTT, 2.0 mm EDTA and 1 mg/mL bovine serum albumin (BSA)) at 37°C for 1 h, and added 0.25 mm nicotin amide adenine dinucleotide phosphate (NADPH), 0.4 nm mal onylCoA, 0.06 mm acetylCoA, and 0.02 µCi [ 3 H] acetylCoA, then the reaction was terminated by 60% HClO 4 . Fatty acids were extracted with 1 mL of hexane and incorporation of ra dioactivity into the fatty acids was assessed by scintillation counting.
Flow Cytometric Analysis Cells with 10 5 cells/mL were suspended in 300 µL PBS and 700 µL ethanol was added. Cells were incubated at 4°C for 1 h and washed with PBS, and suspended in 250 µL of 1.12% sodium citrate buffer (pH 8.4) together with 0.125 units of RNase. Incubation was continued at 37°C for 30 min. The cellular DNA was stained by apply ing 250 µL of PI (50 µg/mL) for 30 min at room temperature. The stained cells were analyzed by fluorescent activated cell sorting (FACS) on the BD FACSCanto™II flow cytometer using FACSCanto™II System Software for the percentage of apoptotic cells.
Wound Migration Assay Cells were seeded in 6well plates and incubated for 18 h in serum free McCoy's 5A. The cellular monolayer was wounded with a sterile 10 µLpipette tip and washed with serum free McCoy's 5A to remove de tached cells from the plates. The cells were incubated in the presence or absence of pristimerin for 48 h in MaCoy's 5A containing 10% FBS. The medium was replaced with PBS, and the cells were photographed using a phasecontrast mi croscope.
Transwell Invasion Assay Cell invasion assay was car ried out with BD Biocoat™ Transwell Invasion Chambers with inserts. Each insert is equipped with 6.4 mm in diameter, 8 µm pore size PET porous membrane which has been coated with Matrigel Matrix (BD Bioscience, Bedford, U.S.A.). Cells (2.5×10 4 ) suspended in 300 µL of serum free MaCoy's 5A with or without pristimerin were added to the upper chamber; 500 µL of MaCoy's 5A containing 10% FBS were added to the lower chamber of 24well plates. After incubation for 24 h, noninvading cells were removed from the upper surface of the membrane by scrubbing, and invading cells on the lower surface of the membrane were stained hematoxylin. Mem branes were then removed and invading cells were counted randomly by light microscopy. Each assay was performed in triplicate and repeated at least 3 times. Due to variation in the number of migrated cells from different experiment, the results are normalized to control cells and the relative inva sion is expressed as mean± S.D. of migrating cells relative to control cells.
RESULTS
Pristimerin Inhibits the Proliferation of SKBR3 Cells
New treatment strategies are needed for patients with ad vanced HER2positive breast cancers due to very limited therapeutic options available for fighting this disease. Over expression of HER2 in SKBR3 human breast cancer cells is due to endogenous gene amplification. We assessed the effect of pristimerin on the proliferation of SKBR3 cells using the CCK8 assay. Cells were treated with 0, 0.1, 0.5, 1, 5, and 10 µm of pristimerin for 6, 12, and 24 h. Treatment with pristimerin significantly inhibited the proliferation of cells in dose and timedependent manners (Figs. 1B, C) .
Pristimerin Downregulates HER2 Expression We found that pristimerin inhibits growth in SKBR3 cells. To further investigate whether the inhibitory proliferation was caused by the regulation of HER2 in HER2positive cells, both HER2 protein and its phosphorylation levels were de termined by Western blotting. Pristimerin dose and time dependently downregulated HER2 and HER2 phosphorylation levels in SKBR3 cells (Figs. 2A, B) . To determine the mecha nism of HER2 downregulation by pristimerin, we analyzed HER2 mRNA levels by RTPCR. As a result, a decrease in HER2 mRNA levels was observed after pristimerin treatment (Fig. 2C) . We conclude that pristimerin decreased HER2 at both mRNA and protein level.
Pristimerin Suppresses FASN Expression HER2 regu lates FASN expression through PI3K/Akt signal transduction pathways, revealing a molecular connection between HER2 and FASN. 25) To investigate their inhibitory activity on FASN protein level in HER2positive cells, we treated SKBR3 cells with pristimerin (0.1, 0.5, 1, 5, 10 µm) for 24 h, and FASN protein levels were analyzed by Western blotting. Similar to HER2 downregulation, pristimerin was effective for suppress ing FASN expression (Fig. 3A) . We confirmed that pristimerin altered FASN activity in SKBR3 cells, indicating that FASN activity was inhibited by pristimerin (Fig. 3B) . To confirm that the antiproliferation effect induced by pristimerin was related to FASN inhibition, cells were treated with pristimerin (10 µm) for 24 h in the presence of palmitate (75 µm). Adding exogenous palmitate reduced the proliferation activity of pris timerin (Fig. 3C) . The changes in HER2 and FASN expression induced by pristimerin were confirmed by the levels of Akt and MAPK phosphorylation (Erk, p38, JNK). Pristimerinin duced tyrosine phosphorylation of Akt, Erk1/2, p38, and JNK was inhibited in SKBR3 cells, whereas total expression of Akt, Erk1/2, p38, JNK was unchanged (Fig. 3D) . Furthermore FASN and HER2 expression was also synergistically inhibited by the PI3K inhibitor (LY294002), Erk inhibitor (PD98059), JNK inhibitor (SP600125), and p38 inhibitor (SB20356) (Fig.  3E) . These data indicate that pristimerin is involved in the suppression of FASN physiological function in HER2positive SKBR3 cells, suggesting an interaction between HER2 and FASN.
Pristimerin Downregulates the mTOR/p70S6K/4EBP1 Pathway and Inhibits Metastasis Because of the pristimer ininduced connection between HER2 and FASN in SKBR3 cells, we focused on further signaling pathways regulated by HER2 and FASN downregulation. HER2 overexpression in breast cancer is often associated with aberrant activation of the mTOR pathway. 14, 26) To investigate the molecular changes in SKBR3 cells after pristimerin treatment, we analyzed the expression and phosphorylation of proteins relevant to mTOR signaling. The results showed that treatment with pristimerin dosedependently lowered the levels of phosphorylated mTOR compared to those in vehicle treated cells (Fig. 4A) . Addi tionally, pristimerin inhibited activity of mTOR downstream targets, such as p70S6K and 4EBP1 (Fig. 4A) . Clinical tri als using rapamycin analogues, such as temsirolimus and everolimus, registered for treatment of advanced renal cancer, have validated the importance of inhibiting mTOR as an anti cancer treatment strategy. 23) To further investigate the com bined effect of pristimerin and rapamycin in SKBR3 cells, we performed Western blotting to measure activation of mTOR. Cells were treated for 24 h with 10 µm pristimerin, 2.7 µm ra pamycin, or a combination of both drugs. When both drugs were used together, a considerable reduction was noted in phosphop70S6K and phospho4EBP1 compared to the single drugs (Fig. 4B) . Taken together, these results suggest that pris timerin inhibited mTOR/p70S6K/4EBP1 pathway in SKBR3 cells. Because HER2 enhances metastasis and angiogenesis by activating the mTOR/p70S6K pathway in human breast cancer cells, 14) we examined the effect of pristimerin on SKBR3 cell migration in a wound migration assay. The migration distance between the leading edge and the wound line was compared between pristimerintreated and untreated cells. Cell motility was controlled by 5 µm pristimerin, and rapamycin addition ally increased this activity (Fig. 4C) . Next, cells were treated with or without pristimerin for 48 h to determine whether pristimerin also inhibits cell invasion. Treatment of cells with 5 µm pristimerin decreased invasive activity. Additionally, the pristimerininduced decrease in Matrigel invasion decreased more following rapamycin treatment (Fig. 4D) . Collectively, these results show that pristimerininduced mTOR inhibition # p<0.05 vs. pristimerintreated cells (D) Cell lysates from SKBR3 cells were subjected to Western blotting for Erk1/2, p38, JNK, phosphoErk1/2 (Thr202/Tyr204), phosphop38 (Thr180/Tyr182), phosphoJNK (Thr183/Tyr185), and β-actin. Three independent experiments were performed. (E) Cells were exposed to PI3K inhibitor (LY294002), Erk inhibitor (PD98059), JNK inhibitor (SP600125), and p38 inhibitor (SB20356). After pristimerin (2 µm) treatment for 24 h, the HER2 and FASN protein expression levels were analyzed by Western blotting. Three independent experiments were performed. reduced migration and invasion of SKBR3 cells.
Pristimerin Promotes Caspase-Dependent Apoptotic Cell Death Several studies have suggested that inhibiting mTOR could contribute to cell apoptosis. [27] [28] [29] We examined whether cytotoxic effects were due to an increase in apoptotic cell death. The percentage of apoptotic cells in the subG 1 phase of pristimerin-treated cells was measured by flow cy tometry. Compared with the vehicletreated control, pristime rin dramatically increased the number of apoptotic cells (Fig.  5A) . To investigate the biochemical features that lead to apo ptosis induced by pristimerin, we examined the effects of pris timerin on caspase3, 8, and 9, and PARP activation. Cells were treated with pristimerin (10 µm) for 24 h, and samples were collected and blotted with antibodies that recognize the inactive forms of the caspases. Following treatment with 1 µm, reductions of the inactive forms of PARP and caspases3, 8, and 9 could already be observed, and the bands disappeared completely after treatment with 10 µm pristimerin, indicating their full activation (Fig. 5B) . Pretreatment of cells for 1 h with 100 µm zVADfmk, a pancaspase inhibitor, eliminated apoptotic cells (Fig. 5C ) and PARP cleavage (Fig. 5D) . Taken together, caspasedependent apoptotic cell death increased fol lowing pristimerin treatment.
DISCUSSION
We examined the effect of pristimerin ((20α)-3-hydroxy-2-oxo-24-nor-friedelan-1(10),3,5,7-tetraen-carboxylic acid-(29)-methylester, C 30 H 40 O 4 ) on the cytotoxic mechanism of HER2-positive SKBR3 human breast cancer cells. Pristimerin is a potent antitumor agent in a wide range of different human cancers, including breast cancer, prostate cancer, cervical can cer, and leukemia. 6, 8, 10, 30) However, the mechanism involved in the cytotoxic effect of pristimerin in cancer cells has not been fully explored. The nontumorogenic human mammary epithelial cell line MCF10A was less sensitive to pristimerin in a previous study, 6) and we also investigated the cytotoxicity of pristimerin using NIH-3T3 fibroblasts, resulting in non-tox icity at concentrations up to 50 µm (data not shown). These re sults suggest that pristimerin has therapeutic potential in can cers. In a previous study, pristimerin was highly toxic to cell lines with IC 50 values ranging from 0.55 µm (MDAMB435) to 3.2 µm (K562). 30) In addition, pristimerin inhibits cell growth of the A594 (lung), MCF7 (breast), HepG2 (hepato carcinoma), and Hep3B (liver) cancer cell lines with IC 50 val ues of 0.42-0.61 µm. 6) This present study also showed similar data with those of others, showing an IC 50 value 2.4 µm after 24 h in the SKBR3 human breast cancer cell line (Fig. 1) . The SKBR3 cell line overexpresses the HER2/erbB2 oncogene product. HER2 overexpression has been correlated with poor prognosis, enhanced metastatic potential, increased chemo resistance, and the regulation of a variety of vital functions, such as cell growth, differentiation, and apoptosis, of human cancers. 31) In this study, we demonstrated for the first time, that pristimerin inhibited HER2 expression in HER2-positive SKBR3 cells (Figs. 2A, B) . Pristimerin also reduced HER2 mRNA levels (Fig. 2C) , suggesting that pristimerin downregu lates HER2 expression by diminishing HER2 gene transcrip tion. Together with the antiproliferative activity of pristimerin in Fig. 1 , these results suggest that the anticancer activity of pristimerin on HER2positive SKBR3 cells is mediated by de pleting HER2 from cancer cells. To test whether the effects of pristimerin decreased HER2 expression and cell growth, we evaluated the activities using another HER2positive gastric cancer cell line (NCI-N87). As a result, HER2 expression and cell growth were downregulated in NCIN87 cells following pristimerin treatment (data not shown) and showed a growth inhibitory effect (IC 50 of approximately 7 µm after 24 h). Al though pristimerin has broad cytotoxicity in various cancer cell lines, these data show that downregulation of HER2 gene expression by pristimerin may lead to cell toxicity.
FASN is a homodimeric multienzymatic protein of 250-270 kDa that is divided into seven functional domains assembled into two homodimers. 32) Through a series of 32 reactions, FASN is able to synthesize long chain fatty acids, mainly palmitate, using acetylCoA and malonylCoA as sub strates and nicotinamide adenine dinucleotide phosphate as an electron donor. 33) FASN expression remains at low levels and its regulation is complex and highly dependent on nutritional status and on the hormonal profile in normal cells. 33) However, FASN expression and activity are a common phenotype in most human tumor cells, demonstrating that FASN plays an essential role in tumor growth and survival.
34) The pathways responsible for FASN overexpression in cancer cells are not yet well understood. Four different mechanisms have been proposed, including enhanced transcription, increased trans lation, greater stability of proteins, and gene amplication. 35) These mechanisms may be active at the same time and may prevent FASN from physiological regulation; thus, resulting in constitutive activation of the lipogenic pathway in tumors. 25) FASN is highly expressed in a large number of human can cers, including breast, colon, ovary, pancreas, and prostate cancers. 36) Several breast cancer studies have demonstrated an association between FASN expression and disease prognosis. Patients with stage I breast cancer and high levels of FASN show a fourfold increased risk of death from this pathology than patients with lower FASN protein levels. 37) FASN expres sion has also been associated with HER2 expression in poor prognosis tumors, suggesting that FASN is a potential thera peutic target for treatment of HER2positive breast cancer. In this study, we observed that pristimerin inhibited FASN expression and FASN activity dose-dependently (Figs. 3A, B) , and further analysis indicated that the pristimerininduced anti-proliferation effect was reduced by exogenous treatment with palmitate in HER2positive SKBR3 cells (Fig. 3C) . In previous reports, the addition of exogenous palmitate mark edly suppresses the cytotoxic effects of natural FASN inhibi tors such as luteolin and amentoflavone in breast cancer cell lines. 38, 39) 25) The JNK pathway rep resents one subgroup of MAPK and plays a role in the induc tion of apoptosis, cell survival, and proliferation. 42) JNK sig naling plays a role in FASN expression and apoptosis. 43, 44) It is important that HER2 and FASN expression in cancer cells occurs in most cases through the same signaling pathways (MAPK/Erk1). 45) In this study, Akt and MAPK phosphoryla tion (Erk, p38, JNK) was suppressed by pristimerin treatment in SKBR3 cells (Fig. 3D) . Furthermore FASN and HER2 expression was also synergistically inhibited by the PI3K in hibitor (LY294002), Erk inhibitor (PD98059), JNK inhibitor (SP600125), and p38 inhibitor (SB20356) (Fig. 3E) . These data support that HER2 regulates FASN expression through Aktdependent and/or MAPKsdependent mechanisms.
A clear association exists between mTOR activation and HER2 overexpression in breast cancers, 26) and activation of the mTOR signaling pathway has been associated with poorer prognoses. The mTOR signaling pathway plays an important role in FASN upregulation in HER2-overexpressing cancer cells. 46, 47) Many reports have suggested that the mTOR path way plays a role in the susceptibilities of chemopreventive or chemotherapeutic agents to kill cancer cells. 48, 49) Therefore, blocking the mTOR pathway provides a promising target for novel therapeutic strategies. In this study, we demonstrated that pristimerin inhibited mTOR phosphorylation and phos phorylation of its substrates p70S6K and 4EBP1 in HER2 positive SKBR3 cells (Fig. 4A) . Moreover, the mTOR inhibitor rapamycin synergistically enhanced pristimerin activity (Fig.  4B) . To test whether the pristimerininduced downregula tion of HER2 blocks mTOR signaling, we evaluated the ac tivities using another HER2positive gastric cancer cell line (NCIN87), which revealed similar results to those of SKBR3 cells (data not shown). The mTOR pathway, which is aber rantly activated in the majority of invasive breast cancers, is involved in many cellular processes including invasion and tumor angiogenesis. 50, 51) In addition, HER2 overexpression has been demonstrated to increase invasive gene expression (matrix metalloproteinase [MMP]2 and MMP9) in mammary epithelial cells; 52) HER2 increases angiogenesis and spontane ous metastasis of human breast cancer cells via activation of mTOR/p70S6K. 14) Although HER2 activates the mTOR path way, the role of mTOR signaling in HER2mediated cancer metastasis and angiogenesis remains unclear. We found that pristimerin inhibited migration and invasion activities through mTOR signaling (Figs. 4C, D) . Taken together, these results suggest that targeting the mTOR pathway using pristimerin may be a potential adjuvant strategy to inhibit migration and invasion of highly metastatic cancers. Dual mTOR and HER2 blockade results in antitumor activities in HER2resistant breast cancers. 53) Therefore, direct inhibition of mTOR signal ing is an attractive clinical strategy for this disease. Combi nation therapies in which both the mTOR pathway and key reactivated targets such as HER2 are inhibited together may result in improved efficacy. 53) Apoptosis is a key mechanism by which anticancer drugs kill tumor cells, which is a cellular suicide program through the mitochondrial (intrinsic) or death receptor pathways (extrinsic). 54) One mechanism is the mitochondrial pathway, which is activated by the release of proapoptotic factors (cy tochrome c) from mitochondria. 55) The released cytochrome c interacts with Apaf1 and activates caspase9, which, in turn, proteolytically activates downstream caspase3, one of the principle proteases participating in the execution phase of apoptosis.
6) Activated caspase3 cleaves many substrates in cluding PARP, a DNA repair enzyme, and leads to inevitable cell death.
6) The other pathway, the death receptor pathway, involves Fas and other members of the tumor necrosis fac tor receptor family, which activate caspase8. 56) Caspase8 activates downstream events by directly activating caspase3, which then triggers the mitochondrial pathway. 6) Pristimerin directly induces release of cytochrome c from mitochondria and activates the caspase cascade. 6) Pristimerin induces apo ptosis by targeting the proteasome in prostate cancer cells. 8) Pristimerin induces apoptosis in imatinibresistant chronic myelogenous leukemia cells harboring the T315I mutation by blocking NFκB signaling and depleting BcrAb1. 57) However, the mechanism for apoptosis by pristimerin has not been fully explored. In this study, we confirmed that pristimerin induces apoptotic cell death (Fig. 5A ) and activates caspase3, cas pase9, followed by PARP cleavage, which are modulators in the mitochondrial pathway (Fig. 5B) . Inhibiting caspase acti vation by zVADfmk prevented pristimerininduced apoptosis (Figs. 5C, D) . Interestingly, we found that pristimerin induced apoptosis via the cell death receptor pathway (extrinsic) by activating caspase-8 and caspas-3 (Fig. 5B) . This is the first report that pristimerin induces apoptosis via the extrinsic apoptotic pathway. One supportive study showed that apigenin induces apoptosis via the extrinsic pathway in HER2-positive breast cancer cells 58) ; however, we suggest that further investi gation is needed to identify the molecular mechanism of pris timerininduced apoptosis targeting HER2positive cancers.
Taken together, pristimerin represents a novel HER2target ed compound that is able to decrease fatty acid synthase and modulate Akt, MAPKs (Erk, JNK, p38), and mTOR signaling pathways to influence metastasis and apoptotic cell death. Our results suggest that pristimerin may be a potential agent for cancer prevention and treatment of HER2positive human cancers.
